Combined effect of total nucleated cell dose and HLA match on transplantation outcome in 1061 cord blood recipients with hematologic malignancies.
about
Review on Haploidentical Hematopoietic Cell Transplantation in Patients with Hematologic MalignanciesNovel Techniques for Ex Vivo Expansion of Cord Blood: Clinical TrialsUmbilical cord blood: an evolving stem cell source for sickle cell disease transplantsAdvances in haplo-identical stem cell transplantation in adults with high-risk hematological malignanciesReasons for exclusion of 6820 umbilical cord blood donations in a public cord blood bank.Dominant unit CD34+ cell dose predicts engraftment after double-unit cord blood transplantation and is influenced by bank practice.Cord blood collection and banking from a population with highly diverse geographic origins increase HLA diversity in the registry and do not lower the proportion of validated cord blood units: experience of the Marseille Cord Blood Bank.Umbilical cord blood expansion with nicotinamide provides long-term multilineage engraftmentA preclinical model of double- versus single-unit unrelated cord blood transplantation.Umbilical cord blood transplantation: the first 25 years and beyond.Rapid induction of single donor chimerism after double umbilical cord blood transplantation preceded by reduced intensity conditioning: results of the HOVON 106 phase II study.Hematopoietic stem cell transplantation for infantile osteopetrosis.Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS.How I treat: the selection and acquisition of unrelated cord blood grafts.Thrombopoietin treatment of one graft in a double cord blood transplant provides early platelet recovery while contributing to long-term engraftment in NSG mice.Influence of infused cell dose and HLA match on engraftment after double-unit cord blood allografts.Transplant physicians' perceptions of cord blood transplantation in Korea: a questionnaire surveyHigh day 28 ST2 levels predict for acute graft-versus-host disease and transplant-related mortality after cord blood transplantation.Reduced late mortality risk contributes to similar survival after double-unit cord blood transplantation compared with related and unrelated donor hematopoietic stem cell transplantation.Impact of long-term cryopreservation on single umbilical cord blood transplantation outcomes.A comparison of immune reconstitution and graft-versus-host disease following myeloablative conditioning versus reduced toxicity conditioning and umbilical cord blood transplantation in paediatric recipients.Reduced-intensity conditioning with combined haploidentical and cord blood transplantation results in rapid engraftment, low GVHD, and durable remissions.Correlation of infused CD3+CD8+ cells with single-donor dominance after double-unit cord blood transplantation.Indirect evidence that maternal microchimerism in cord blood mediates a graft-versus-leukemia effect in cord blood transplantation.HLA mismatch direction in cord blood transplantation: impact on outcome and implications for cord blood unit selection.Race/ethnicity affects the probability of finding an HLA-A, -B, -C and -DRB1 allele-matched unrelated donor and likelihood of subsequent transplant utilizationEfficiency of high-dose cytarabine added to CY/TBI in cord blood transplantation for myeloid malignancy.Engraftment kinetics and graft failure after single umbilical cord blood transplantation using a myeloablative conditioning regimen.The Cord Blood Apgar: a novel scoring system to optimize selection of banked cord blood grafts for transplantation (CME).Comparison of pre-cryopreserved and post-thaw-and-wash-nucleated cell count on major outcomes following unrelated cord blood transplant in children.A perspective on the selection of unrelated donors and cord blood units for transplantationEarly lymphocyte recovery and outcomes after umbilical cord blood transplantation (UCBT) for hematologic malignanciesThe Role of HLA in Cord Blood Transplantation.Impact of Allele-Level HLA Mismatch on Outcomes in Recipients of Double Umbilical Cord Blood Transplantation.Modelling improvements in cell yield of banked umbilical cord blood and the impact on availability of donor units for transplantation into adults.Risk Factors for Acute and Chronic Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation with Umbilical Cord Blood and Matched Sibling Donors.A review of factors influencing the banking of collected umbilical cord blood unitsIn vivo DPP-4 inhibition to enhance engraftment of single-unit cord blood transplants in adults with hematological malignanciesExtensive haplotype diversity in African American mothers and their cord blood units.Unrelated donor cord blood transplantation for children with severe sickle cell disease: results of one cohort from the phase II study from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN)
P2860
Q26749120-01EAA050-80AC-472A-BBD5-167A45B523C7Q26772216-CD1AD383-753E-4DE1-AD83-5ADF98B3DD86Q26853559-9F2CAAB7-7DB6-4A29-8545-07AB3C4ACFF3Q27014857-01CDA31A-003C-4327-9B5A-1D11AC97C1B6Q33455702-1402CD08-BEB5-4C47-B437-2D98326B6530Q33456839-990143ED-DC77-4253-970D-C143D885A3E6Q33457123-3F0694DB-3E6C-46A4-9FF2-4119FFBDD881Q33808209-A3364353-C24E-48C1-80AA-60ED28516789Q33965521-F32B53E6-52C3-4FF8-9EAD-30D3CFE4FB67Q34344669-C79037E3-3FFC-4520-AEA5-4DEE54D62789Q34463602-4B71D28E-CA19-4797-A106-8965479FA405Q34477968-06602815-2578-458F-8F86-6865A3B9F545Q34684038-F8FA34DD-059B-4E52-B6E9-B83FE16D821EQ34707580-10814CD1-FDBD-4AC4-96B3-E3779692CD59Q34751263-C21E98BB-1E97-4EFB-89A6-F43CCA875609Q34754318-3839A7E8-E101-4004-A581-FD750968617CQ34779382-17A0C20A-3714-4351-B8F2-55B5FB8A5C10Q34802425-94F43C27-88B7-428B-AF8A-00DF2EBB76FCQ35167190-4BB98B47-0465-49AD-BD93-83C383EA0097Q35230664-97084B5D-01A7-43A3-BF12-942E3A59EDE3Q35285087-C3C02127-79A7-4AAE-A867-C6A74FC16BD1Q35608181-BF2D2FBB-BE25-4E5C-BF09-1D3D803452D0Q35711969-BAF01257-F423-46BC-A12A-4959A0D4BE6CQ35786957-37E45704-E8E1-43D6-BE68-71938AE16916Q35794126-EF09E699-404A-4447-BABE-9FB2B7751540Q35845470-123F423A-560F-4896-93C8-3241B13C6263Q35859239-E4148BB7-57DC-4384-8D96-E6C271D1B6B4Q36036346-C369397C-733D-4B11-B12B-9CF239088418Q36050021-4CFA5EA8-639F-4E86-B3CA-15F8183C8F4CQ36080841-8140DB3C-4C3A-47A7-BC6C-36C334C9B4C6Q36100445-0920ABBA-CEE1-4089-9570-64CE87D009D2Q36141575-05EFC8F3-CFCC-4507-B98E-9C901D89E270Q36336608-71364B8A-0046-4E9C-9FAD-EEFCC9DBBBD0Q36578783-40E1EA88-DA57-49BD-A7AB-33B26CCB15C7Q36663513-E1BF3D25-CF80-4885-B9F4-D7C7C6A0BFD5Q36675937-701AAF26-AB1B-4FB6-AAC1-794774286FCDQ36692414-2A3E975E-B051-449F-9D96-67EE612B0DBBQ36715531-D79708CD-4B9D-489F-B45B-917077DD8756Q36728749-2413A050-6DEA-4EFA-B982-F6DDF0CA68E0Q36745209-973F7E37-2B68-4D7E-8967-0F956CAFE2B1
P2860
Combined effect of total nucleated cell dose and HLA match on transplantation outcome in 1061 cord blood recipients with hematologic malignancies.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 22 December 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Combined effect of total nucle ...... with hematologic malignancies.
@en
Combined effect of total nucle ...... with hematologic malignancies.
@nl
type
label
Combined effect of total nucle ...... with hematologic malignancies.
@en
Combined effect of total nucle ...... with hematologic malignancies.
@nl
prefLabel
Combined effect of total nucle ...... with hematologic malignancies.
@en
Combined effect of total nucle ...... with hematologic malignancies.
@nl
P2093
P2860
P1433
P1476
Combined effect of total nucle ...... with hematologic malignancies.
@en
P2093
Andromachi Scaradavou
Cladd E Stevens
Juliet N Barker
P2860
P304
P356
10.1182/BLOOD-2009-07-231068
P407
P577
2009-12-22T00:00:00Z